Pancreatic Cancer Research

ResearcherAzienda USL Toscana Nord OvestNo recent work listed

Maurizio Cantore

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3360-499X; OpenAlex author ID A5043872623. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
74
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 14

  1. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  2. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  3. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  4. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  5. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  6. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  7. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  8. AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0108057↗
  9. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Co-author DOI 10.2217/pgs.13.225↗
  10. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Co-author DOI 10.1002/ijc.28078↗
  11. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  12. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1002/bjs.8789↗
  13. Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer. Last author DOI 10.1097/mpa.0b013e3182164002↗
  14. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Last author DOI 10.2217/pgs.11.109↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrea Mambrini · 10 shared papers, 2011–2021 · strength 0.39
  2. Niccola Funel · 6 shared papers, 2011–2017 · strength 0.20
  3. Claudio Bassi · 4 shared papers, 2011–2021 · strength 0.18
  4. Michèle Milella · 3 shared papers, 2013–2021 · strength 0.16
  5. Giuseppe Malleo · 2 shared papers, 2017–2021 · strength 0.14
  6. Giovanni Butturini · 2 shared papers, 2016–2021 · strength 0.14
  7. Giammaria Fiorentini · 2 shared papers, 2011–2021 · strength 0.13
  8. Godefridus J. Peters · 4 shared papers, 2011–2014 · strength 0.13
  9. Elisa Giovannetti · 4 shared papers, 2011–2014 · strength 0.13
  10. Alessandro Giardino · 2 shared papers, 2012–2021 · strength 0.13
  11. Roberto Girelli · 2 shared papers, 2012–2021 · strength 0.13
  12. Isabella M. Frigerio · 2 shared papers, 2012–2021 · strength 0.13
  13. Roberto Salvia · 2 shared papers, 2012–2021 · strength 0.13
  14. Nathalia A. Giese · 3 shared papers, 2013–2017 · strength 0.11
  15. Maria Gazouli · 3 shared papers, 2013–2017 · strength 0.11
  16. Federico Canzian · 3 shared papers, 2013–2017 · strength 0.11
  17. Renata Talar‐Wojnarowska · 3 shared papers, 2013–2017 · strength 0.11
  18. Ewa I. Malecka-Panas · 3 shared papers, 2013–2017 · strength 0.11
  19. Gabriele Capurso · 3 shared papers, 2013–2017 · strength 0.11
  20. Daniele Campa · 3 shared papers, 2013–2017 · strength 0.11
  21. Francesca Tavano · 3 shared papers, 2013–2017 · strength 0.11
  22. Pavel Souček · 3 shared papers, 2013–2017 · strength 0.11
  23. Raffaele Pezzilli · 3 shared papers, 2013–2017 · strength 0.11
  24. Cosmeri Rizzato · 3 shared papers, 2013–2017 · strength 0.11
  25. Amir Avan · 3 shared papers, 2013–2014 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.